-

Agilent Named to Dow Jones Sustainability Indices for Ninth Consecutive Year

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has again been included in the Dow Jones Sustainability World Index and the North America Index for its strong environmental, social, and governance (ESG) performance.

“It’s an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team’s progress in reducing emissions throughout our value chain and providing innovative solutions to help our customers reach their environmental goals,” said Neil Rees, head of Agilent’s ESG programs.

Only 3,500 of the largest companies globally are eligible for inclusion in any Dow Jones Sustainability Index (DJSI), according to S&P Global. Inclusion in the indices is based largely on S&P Global’s annual Corporate Sustainability Assessment (CSA), which invites 13,000 companies to be scored on a wide range of sustainability criteria, from climate strategy and human capital management to business ethics and supply chain management.

The S&P CSA scored Agilent “very high” on sustainability performance, far above the industry average in all three categories.

Agilent is named in both the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index. The World Index tracks the performance of sustainability leaders in the top 10% of the 2,500 largest companies globally, while the North America Index tracks the top 20% of the 600 largest Canadian and U.S. companies in the S&P Global Broad Market Index. It marks the ninth year in which Agilent has been featured in the DJSI.

Agilent has the most comprehensive circular economy program for lab instruments, which includes trade-in, buy-back, recycling, and refurbishing services; a large and growing number of ACT-labeled products; and a wide variety of instruments, consumables, and technology designed to reduce lab energy consumption, waste, and use of fossil fuels. Learn more about Agilent’s ESG programs and progress at Agilent.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc. Logo
Agilent Technologies Inc. Logo

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom